Ideaya, Merck to Evaluate IDE161 in Combination with KEYTRUDA

 

• Trial will evaluate IDE161, IDEAYA's investigational PARG inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with MSI-high and MSS endometrial cancer
   
• Potential first-in-class PARG inhibitor, in combination with anti-PD-1 therapy, targets two complementary mechanisms of anti-tumor immune response in endometrial cancer
   
• IDEAYA will sponsor the clinical trial and Merck will provide KEYTRUDA 

https://www.prnewswire.com/news-releases/ideaya-announces-clinical-collaboration-to-evaluate-ide161-in-combination-with-keytruda-pembrolizumab-in-patients-with-endometrial-cancer-302085972.html